CAMP4 Therapeutics Corporation (NASDAQ:CAMP) saw its stock skyrocket 200% after announcing an oversubscribed private placement that could raise up to $100 million to support its lead program targeting SYNGAP1-related disorders.

The biotech firm has already raised $50 million upfront through sales of common stock at $1.53 per share and pre-funded warrants. An additional $50 million could be unlocked once the company achieves certain milestones, including regulatory approval to launch a Phase 1/2 clinical trial for its SYNGAP1 candidate, expected to begin as soon as the second half of 2026.

“With this financing we are well positioned to bring a potential first-in-class treatment for SYNGAP1-related disorders into the clinic,” said Josh Mandel-Brehm, President and Chief Executive Officer of CAMP4.

The round was led by Coastlands Capital and joined by several other investors, including Janus Henderson Investors, Balyasny Asset Management, Vivo Capital, 5AM Ventures, Adage Capital Management LP, Trails Edge Capital Partners, and the SynGAP Research Fund. Leerink Partners acted as the lead placement agent.

In conjunction with the financing, CAMP4 revealed leadership updates. Doug Williams, Ph.D., who joined the board earlier this year, will step into the role of Board Chair, while Daniel Tardiff, Ph.D. has been promoted to Chief Scientific Officer, effective October 1, 2025.

CAMP4’s research is centered on developing regulatory RNA-based therapies designed to boost gene expression and restore protein levels in patients with genetic conditions. The company said proceeds will be used for preclinical and clinical development of its SYNGAP1 program, as well as general corporate purposes and working capital.

CAMP4 Therapeutics Corporation stock price

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.
Some portions of this content may have been generated or assisted by artificial intelligence (AI) tools and been reviewed for accuracy and quality by our editorial team.